Article in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Keita MiyakawaDepartment of Diagnostic Pathology, Asahikawa Medical University Hospital, Asahikawa 078-8510, Japan.
Kyohei OyamaDepartment of Cardiac Surgery, Asahikawa Medical University, Asahikawa 078-8510, Japan.ORCID 0000-0002-8478-4417
Jiayao LiuDepartment of Diagnostic Pathology, Asahikawa Medical University Hospital, Asahikawa 078-8510, Japan.ORCID 0009-0006-5244-5230
Naoko AkiyamaDepartment of Diagnostic Pathology, Asahikawa Medical University Hospital, Asahikawa 078-8510, Japan.
Akira SakataDepartment of Diagnostic Pathology, Asahikawa Medical University Hospital, Asahikawa 078-8510, Japan.
Manami HayashiDepartment of Diagnostic Pathology, Asahikawa Medical University Hospital, Asahikawa 078-8510, Japan.
Yuki KamikokuraDepartment of Diagnostic Pathology, Asahikawa Medical University Hospital, Asahikawa 078-8510, Japan.ORCID 0000-0001-6087-6440
Naoko AokiDepartment of Diagnostic Pathology, Asahikawa Medical University Hospital, Asahikawa 078-8510, Japan.
Sayaka YuzawaDepartment of Diagnostic Pathology, Asahikawa Medical University Hospital, Asahikawa 078-8510, Japan.ORCID 0000-0002-2337-4000
Shin IchiharaDepartment of Diagnostic Pathology, Asahikawa Medical University Hospital, Asahikawa 078-8510, Japan.ORCID 0000-0002-0211-906X
Takaaki SasakiDivision of Respiratory Medicine and Neurology, Department of Internal Medicine, Asahikawa Medical University, Asahikawa 078-8510, Japan.ORCID 0000-0002-6505-8786
Masahiro KitadaDepartment of Thoracic Surgery and Breast Surgery, Asahikawa Medical University Hospital, Asahikawa 078-8510, Japan.
Yusuke MizukamiDivision of Gastroenterology, Department of Medicine, Asahikawa Medical University, Asahikawa 078-8510, Japan.ORCID 0000-0002-1068-7024
Mishie TaninoDepartment of Diagnostic Pathology, Asahikawa Medical University Hospital, Asahikawa 078-8510, Japan.
Funding
Grant-in-Aid for Scientific Research (KAKENHI) from the Japan Society for the Promotion of Science JP22K06935
6 · The paper itself
Abstract
Lung squamous cell carcinoma (LUSC) tends to arise in the setting of interstitial or emphysematous lung diseases, including idiopathic pulmonary fibrosis (IPF), pulmonary emphysema (PE), and smoking-related interstitial fibrosis (SRIF), where field cancerization may extend. DNA methylation of promoter regions of
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.